Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Fierce Pharma
CDC 'strongly recommends' Gilead's HIV PrEP Yeztugo
In its recommendation, the CDC noted that Gilead's twice-yearly HIV PrEP Yeztugo could "improve PrEP adherence and thus enhance HIV prevention."
Zoey Becker
Sep 19, 2025 11:22am
Fierce Pharma
CVS won't cover Gilead's twice-yearly PrEP drug Yeztugo—for now
Aug 21, 2025 3:02pm
A look inside Caremark's strategy for improving health equity
Sep 12, 2022 7:20am
OIG: Part D plans sidestepped cheaper hep C generics
Aug 11, 2022 3:56pm
Judge slims UnitedHealth's HIV drug suit against Gilead, Teva
Mar 9, 2022 12:20pm
Insurers sue pharmas, allege anticompetitive HIV drug scheme
Dec 15, 2021 11:35am
